CARL IVAN DENIS: Open Payments
NPI 1700396801 · NORTH MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,972 in 107 payments from 13 companies in 2025. Trend: 2023 $3,450 · 2024 $2,294 · 2025 $3,972
Food & beverage: $3,859Education: $113
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $902 |
| Janssen Pharmaceuticals, Inc | 21 | $615 |
| Neurocrine BioSciences, Inc. | 16 | $597 |
| Vanda Pharmaceuticals Inc. | 11 | $365 |
| E.R. Squibb & Sons, L.L.C. | 7 | $365 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $361 |
| Alkermes, Inc. | 12 | $347 |
| Indivior Inc. | 4 | $280 |
| ABBVIE INC. | 2 | $45 |
| Luye Pharma (USA) Ltd. | 2 | $40 |
Products named: INVEGA SUSTENNA, INGREZZA, UZEDY, COBENFY, CAPLYTA, FANAPT, AUSTEDO XR, ARISTADA.
Industry payments across FL — which companies pay providers there.
